Clinical Trial Update: Study of XPF-001 in the Treatment of Pain From Primary/Inherited Erythromelalgia (IEM) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial investigating XPF-001 for pain associated with primary and inherited erythromelalgia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Erythromelalgia
• Inherited Erythromelalgia

Drugs mentioned

• XPF-001

Snippet

Sponsor: Xenon Pharmaceuticals Inc. | Conditions: Primary Erythromelalgia, Inherited Erythromelalgia | Phase 1, Phase 2 | Status: COMPLETED